FILANA THERAPEUTICS, INC.
About FILANA THERAPEUTICS, INC.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2013
- $41.1M
- Net income
- -$91.0M
- Total assets
- $118.4M
- Market cap
- $63.8M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $63.8M
- Shares outstanding
- 44.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 14, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $91.0M in FY2013.
- Trading 32% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review FILANA THERAPEUTICS, INC..
